IPSC - NASDAQ

Century Therapeutics, Inc.

IPSC·NASDAQ

$2.07

-5.5%

HealthcareBiotechnology

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$179.20M

EPS-0.1100

P/E Ratio-18.82

Earnings Date08/13/2026

-7.22%

Return on Invested Capital

-88%

3Y-75.0%

5Y-86.0%

10Y-97.0%

-6.03%

Return on Equity

-92%

3Y-86.0%

5Y-112.0%

10Y-102.0%

-4.28%

Return on Assets

-88%

3Y-84.0%

5Y-91.0%

10Y-98.0%

Century Therapeutics, Inc. Management Team

IPSC · NASDAQ

Dr. Adrienne Farid Ph.D.

Chief Development Officer & Head of Early Development

Compensation

$742,331

Born 1962(Age 64)

Dr. Morgan Conn Ph.D.

Chief Financial Officer

Born 1969(Age 57)

Dr. Chad A. Cowan Ph.D.

Chief Scientific Officer

Born 1972(Age 54)

Dr. Gregory Russotti Ph.D.

Chief Technology & Manufacturing Officer

Compensation

$812,631

Born 1967(Age 59)

Dr. Brent Pfeiffenberger M.B.A., Pharm.D.

President, Chief Executive Officer & Director

Compensation

$1,708,667

Born 1978(Age 48)

Ms. Katja Buhrer

SVice President, Head of Corporate Affairs & Strategy

Born 1982(Age 44)

female

Dr. Nick Trede M.D., Ph.D.

Senior Vice President & Head of Clinical Development

Michael Naso Ph.D.

Senior Vice President of Cell Engineering

Mr. Douglas Carr CPA

Senior Vice President of Finance & Operations and Secretary

male

INSIDER TRANSACTIONS

Century Therapeutics, Inc. Insider Positioning

IPSC · NASDAQ

During the last 12 months, insiders have purchased $282K and sold $69K worth of IPSC shares, resulting in $213K of net buying activity.

3 Months

Bought

0.00

Sold

17.9K

45.47K

Net Activity

-45K

-$45K

3-6 Months

Bought

110.1K

79.60K

Sold

1.1K

1.00K

Net Activity

+79K

+$79K

6-9 Months

Bought

35.0K

17.33K

Sold

39.5K

18.29K

Net Activity

-958

-$958

9-12 Months

Bought

308.0K

184.80K

Sold

6.8K

4.17K

Net Activity

+181K

+$181K

Top Buyers

Cowan Chad

Officer: Chief Scientific Officer

58.1K shares•1 transactions

$49K

Pfeiffenberger Brent

Director, Officer: President And Ceo

87.0K shares•2 transactions

$48K

Quimi Daphne

Director

44.0K shares•1 transactions

$26K

Blackwell Kimberly

Director

44.0K shares•1 transactions

$26K

Jimenez Joseph

Director

44.0K shares•1 transactions

$26K

Top Sellers

Russotti Gregory

Officer: See Remarks

12.1K shares•5 transactions

$28K

Carr Douglas

Officer: Svp Finance & Operations

13.6K shares•8 transactions

$23K

Pfeiffenberger Brent

Director, Officer: President And Ceo

33.4K shares•3 transactions

$15K

Cowan Chad

Officer: Chief Scientific Officer

5.5K shares•1 transactions

$3K

Farid Adrienne

Officer: Chief Operations Officer

552 shares•1 transactions

$343

Insider Activity Analysis

Net Insider Sentiment

Bullish

Strong bullish signal with $213K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.

Buy/Sell Ratio

4.09:1

Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.

Recent Trend (3 Months)

$45K

Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.

Insider Participation

Balanced

5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.

Insider Activity Insight

Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.

SEC PROXY FILINGS

SEC Filings

IPSC - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
DEF 14A DEF 14A 2026 N/A	April 27, 2026	June 11, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	December 02, 2025	January 22, 2026	2026	View Filing
DEF 14A DEF 14A 2025 N/A	April 22, 2025	June 12, 2025	2025	View Filing
DEF 14A DEF 14A 2024 N/A	April 26, 2024	June 20, 2024	2024	View Filing
DEF 14A DEF 14A 2023 N/A	April 28, 2023	June 27, 2023	2023	View Filing
DEF 14A DEF 14A 2022 N/A	April 21, 2022	June 09, 2022	2022	View Filing

Showing 1 to 6 of 6 filings

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.